RayKnowChina Research Map
Shortlist0

Nanjing Medical University

南京医科大学

NanjingUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.4%Leads about 1 in 72 of China's research papers on NPC ▼ from 2.2%

Led 33 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
1
Research papers it led
33
Trials it led
5
Share of China's trials
0.8%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Jiangsu Cancer Hospital14
  2. Jiangsu Province Hospital11
  3. Affiliated Suzhou Hospital of Nanjing Medical University Counted in the group total2
  4. Third Affiliated Hospital of Nanjing Medical University Counted in the group total1
  5. Changzhou No.2 People's Hospital Counted in the group total1
  6. Second People's Hospital of Changzhou affiliated to Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. The Impact of Whole-Course Immunonutrition Management on Patients With Stage III and IV Nasopharyngeal Carcinoma Undergoing Concurrent Chemoradiotherapy: A Randomized Controlled Trial.2025Nutrition and cancerRCT
  2. Radiomic analysis based on machine learning of multi-sequences MR to assess early treatment response in locally advanced nasopharyngeal carcinoma.2025Science progressFree full text
  3. Delineation Errors Caused by Replication and Expansion Operations in Monaco.2024Technology in cancer research & treatmentFree full text
  4. Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.2024Oral oncology
  5. Improving the performance of deep learning models in predicting and classifying gamma passing rates with discriminative features and a class balancing technique: a retrospective cohort study.2024Radiation oncology (London, England)Free full text
Trials on ClinicalTrials.gov6
  1. Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal CarcinomaNot yet recruitingNCT05912582Lead sponsorStart 2025-12
  2. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  3. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  4. Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal CarcinomaCompletedNCT06244394Lead sponsorStart 2023-06
  5. A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical ApplicationStatus unknownNCT02980315Lead sponsorPhase 1/Phase 2Start 2016-11
  6. NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent ChemoradiationTerminatedNCT01694576Lead sponsorPhase 2Start 2012-09

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
3.7%Leads about 1 in 27 of China's research papers on ESCC ▼ from 4.9%

Led 108 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
10
Research papers it led
108
Trials it led
17
Share of China's trials
3.0%
Share of the world's papers
2.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025
ThemesImmunotherapyRadiotherapyNeoadjuvant & combined treatment
Papers it led5
  1. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.2022ESMO openRCTFree full text
  2. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.2024Journal for immunotherapy of cancerFree full text
  3. Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial.2023Journal for immunotherapy of cancerFree full text
  4. Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor responders.2026Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  5. The predictive role of PNI and NRS2002 for postoperative pulmonary complications in ESCC patients undergoing neoadjuvant chemoimmunotherapy followed by McKeown esophagectomy: a retrospective cohort study.2025World journal of surgical oncologyFree full text
Trials on ClinicalTrials.gov6
  1. Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and EfficacyEnrolling by invitationNCT07371247Lead sponsorEarly phase 1Start 2025-12
  2. Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07435454Lead sponsorPhase 2Start 2025-12
  3. A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06356688Lead sponsorPhase 2Start 2025-04
  4. Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06988956Lead sponsorPhase 2Start 2024-03
  5. Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell CarcinomaRecruitingNCT06698692Lead sponsorStart 2024-04
  6. Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06563869Lead sponsorPhase 3Start 2024-02

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.7%Leads about 1 in 59 of China's research papers on HCC

Led 250 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
6
Research papers it led
250
Trials it led
11
Share of China's trials
0.8%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Over half of these papers are lab or animal studies.

Papers it led5
  1. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.2022Journal for immunotherapy of cancerFree full text
  2. FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined.2022Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  3. Hypoxia-induced RCOR2 promotes macrophage M2 polarization and CD8+ T-cell exhaustion by enhancing LIF transcription in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  4. eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.2025Journal of hepatology
  5. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.2024Journal of hepatology
Trials on ClinicalTrials.gov6
  1. Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After SurgeryRecruitingNCT06762782Lead sponsorPhase 2Start 2025-02
  2. A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07131501Lead sponsorPhase 2Start 2025-08
  3. Recurrent Liver Cancer: Reconceptualization and ReevaluationRecruitingNCT06430983Lead sponsorStart 2024-07
  4. Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06241326Lead sponsorStart 2024-03
  5. Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingNCT05613478Lead sponsorPhase 3Start 2023-01
  6. Goal-directed LCVP Based on HP in Laparoscopic HepatectomyRecruitingNCT05887661Lead sponsorN/AStart 2022-05

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
3.9%Leads about 1 in 26 of China's research papers on Stomach cancer

Led 378 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
25
Research papers it led
378
Trials it led
41
Share of China's trials
2.8%
Share of the world's papers
1.8%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025
ThemesPeritoneal spread & advanced diseaseImaging & AIEarly detection & endoscopy
Papers it led5
  1. Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Randomized Trial.2025GastroenterologyRCT
  2. Yiqi Huayu Jiedu decoction enhances pathological response in neoadjuvant chemotherapy-treated gastric cancer patients: A prospective, randomized controlled trial.2025Phytomedicine : international journal of phytotherapy and phytopharmacologyRCT
  3. A prospective randomized trial comparing the pocket-creation method and conventional method of endoscopic submucosal dissection in early gastric cancers and precancerous lesions.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCT
  4. Radiomics signature for predicting postoperative disease-free survival of patients with gastric cancer: development and validation of a predictive nomogram.2022Diagnostic and interventional radiology (Ankara, Turkey)RCTFree full text
  5. Machine learning analysis for the noninvasive prediction of lymphovascular invasion in gastric cancer using PET/CT and enhanced CT-based radiomics and clinical variables.2022Abdominal radiology (New York)RCT
Trials on ClinicalTrials.gov6
  1. QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric CancerNot yet recruitingNCT07315035Lead sponsorPhase 2Start 2026-01
  2. 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisRecruitingNCT07914764Lead sponsorStart 2026-08
  3. Robotic vs Laparoscopic Gastrectomy for cT4a Gastric CancerNot yet recruitingNCT07331454Lead sponsorPhase 3Start 2026-02
  4. Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical TrialRecruitingNCT07474324Lead sponsorPhase 2Start 2026-03
  5. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Lead sponsorStart 2026-10
  6. Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOXNot yet recruitingNCT07391826Lead sponsorPhase 2Start 2026-02

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
1.9%Leads about 1 in 51 of China's research papers on Hepatoblastoma

Led 3 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Children's Hospital of Nanjing Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.7%Leads about 1 in 60 of China's research papers on Retinoblastoma

Led 5 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 0020242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Huai'an First People's Hospital3
  2. Affiliated Eye Hospital of Nanjing Medical University1
  3. Changzhou No.2 People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
2.9%Leads about 1 in 35 of China's research papers on Chordoma New since 2021

Led 3 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 002025

Hospitals counted here

  1. Changzhou No.2 People's Hospital1
  2. Jiangsu Province Hospital1
  3. Second Affiliated Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.6%Leads about 1 in 65 of China's research papers on Osteosarcoma ▼ from 2.4%

Led 35 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
35
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
3.8%Leads about 1 in 26 of China's research papers on Gastrointestinal stromal tumour ▲ from 2.9%

Led 20 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
1
Research papers it led
20
Trials it led
2
Share of China's trials
2.7%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025

Hospitals counted here

  1. Jiangsu Province Hospital14
  2. Huai'an First People's Hospital3
  3. Second Affiliated Hospital of Nanjing Medical University2
  4. Affiliated Suzhou Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
2.6%Leads about 1 in 38 of China's research papers on Neuroblastoma ▲ from 1.5%

Led 30 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
3
Research papers it led
30
Trials it led
3
Share of China's trials
7.1%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 222025

Over half of these papers are lab or animal studies.

Papers it led5
  1. Differentiating Benign from Malignant Renal Tumors Using T2- and Diffusion-Weighted Images: A Comparison of Deep Learning and Radiomics Models Versus Assessment from Radiologists.2022Journal of magnetic resonance imaging : JMRIRCT
  2. RAS gene polymorphisms confer the risk of neuroblastoma in Chinese children from Jiangsu province.2025Pediatric surgery international
  3. Cellular morphometric biomarkers and large language model predict prognosis and treatment response in neuroblastoma patients: A retrospective and double-blind prospective single arm clinical study.2025European journal of cancer (Oxford, England : 1990)
  4. HOTTIP rs1859168 C > A polymorphism reduces neuroblastoma susceptibility in Chinese children.2024European journal of pediatrics
  5. Clinical features and treatment options for pediatric adrenal incidentalomas: a retrospective single center study.2024BMC pediatrics
Trials on ClinicalTrials.gov4
  1. Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaRecruitingNCT07195500Lead sponsorStart 2024-12
  2. Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory NeuroblastomaRecruitingNCT06751134Lead sponsorPhase 1Start 2024-12
  3. Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of NeuroblastomaRecruitingNCT07064746Lead sponsorStart 2022-07
  4. Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in ChildrenStatus unknownNCT02919046Study siteN/AStart 2016-09

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
1.2%Leads about 1 in 81 of China's research papers on Ewing sarcoma New since 2021

Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Suzhou Hospital of Nanjing Medical University1
  2. Affiliated Taizhou People's Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Case report and literature review: A young man with giant intra-abdominal Ewing sarcoma.2024Medicine
  2. TIPE1 inhibits the growth of Ewing's sarcoma cells by suppressing Wnt/β-catenin signaling.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
2.3%Leads about 1 in 43 of China's research papers on Myeloma

Led 39 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
6
Research papers it led
39
Trials it led
9
Share of China's trials
1.8%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance

Hospitals counted here

  1. Jiangsu Province Hospital24
  2. Huai'an First People's Hospital6
  3. Affiliated Wuxi People's Hospital of Nanjing Medical University3
  4. Children's Hospital of Nanjing Medical University Counted in the group total1
  5. Affiliated Suqian First People's Hospital of Nanjing Medical University1
  6. First Affiliated Hospital of Kangda College of Nanjing Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.2022Journal for immunotherapy of cancerFree full text
  2. Impact of CD34+ cell infusion dose on immune reconstitution and survival in multiple myeloma after autologous stem cell transplantation.2026Leukemia & lymphoma
  3. A Nomogram for Predicting Progression-Free Survival in Primary Extramedullary Multiple Myeloma Using Routine Laboratory Variables.2026Acta haematologica
  4. The prognostic value of POD24 for multiple myeloma: a comprehensive analysis based on traditional statistics and machine learning.2025BMC cancerFree full text
  5. Progression of disease within 24 months (POD24) in multiple myeloma implicates poor prognosis and limitations of current prediction models for POD24.2024Scientific reportsFree full text
Trials on ClinicalTrials.gov6
  1. Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07628595Lead sponsorEarly phase 1Start 2026-07
  2. RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic MalignanciesNot yet recruitingNCT07113496Lead sponsorPhase 1Start 2025-08
  3. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07294625Lead sponsorEarly phase 1Start 2025-12
  4. Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaRecruitingNCT07907211Lead sponsorPhase 4Start 2024-02
  5. A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple MyelomaRecruitingNCT06497738Lead sponsorStart 2024-05
  6. LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06472479Lead sponsorN/AStart 2024-07

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
1.3%Leads about 1 in 75 of China's research papers on B-ALL

Led 3 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
3
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025
ThemesPhiladelphia chromosome & geneticsChildrenCAR-T & cell therapy

Hospitals counted here

  1. Huai'an First People's Hospital2
  2. Children's Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
2.7%Leads about 1 in 37 of China's research papers on Aplastic anaemia ▲ from 0.8%

Led 11 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025
ThemesImmunosuppressive treatmentThrombopoietin drugsStem cell transplant

Hospitals counted here

  1. Jiangsu Province Hospital9
  2. Affiliated Jiangning Hospital of Nanjing Medical University Counted in the group total1
  3. Affiliated Suzhou Hospital of Nanjing Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
6.3%Leads about 1 in 16 of China's research papers on HLH ▼ from 7.8%

Led 25 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
25
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
1.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesDiagnosis & prognosisLymphoma & cancer-related HLHEBV & infection triggers

Hospitals counted here

  1. Jiangsu Province Hospital22
  2. Second Affiliated Hospital of Nanjing Medical University Counted in the group total1
  3. Affiliated Wuxi People's Hospital of Nanjing Medical University Counted in the group total1
  4. Children's Hospital of Nanjing Medical University Counted in the group total1
  5. Affiliated Suzhou Hospital of Nanjing Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
0.6%Leads under 1 in 100 of China's research papers on Beta thalassaemia New since 2021

Led 2 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. Jiangsu Province Hospital1
  2. Women's Hospital, Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A ▼ from 1.3%

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Sir Run Run Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.8%Leads under 1 in 100 of China's research papers on NMOSD ▼ from 1.4%

Led 4 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025
ThemesAntibodies & diagnosisAcute attack treatment

Hospitals counted here

  1. Affiliated Brain Hospital of Nanjing Medical University3
  2. Jiangsu Province Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
1.2%Leads about 1 in 82 of China's research papers on IgG4-RD

Led 3 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
1
Research papers it led
3
Trials it led
1
Share of China's trials
2.3%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025
ThemesHead, eye socket & salivary glandsTreatment & relapseDiagnosis & look-alikes

Hospitals counted here

  1. Affiliated Suzhou Hospital of Nanjing Medical University Counted in the group total1
  2. Jiangsu Province Hospital Counted in the group total1
  3. Affiliated Taizhou People's Hospital of Nanjing Medical University Counted in the group total1
  4. Affiliated Eye Hospital of Nanjing Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.0%Leads about 1 in 100 of China's research papers on Myasthenia gravis New since 2021

Led 5 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
1
Research papers it led
5
Trials it led
1
Share of China's trials
1.1%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 112025
ThemesBiologic & complement drugsAntibodies & diagnosisPregnancy, children, older adults

Hospitals counted here

  1. Jiangsu Province Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
2.0%Leads about 1 in 51 of China's research papers on Moyamoya

Led 7 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
3
Research papers it led
7
Trials it led
3
Share of China's trials
9.1%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 0020242025: 112025
ThemesGeneticsRevascularisation surgeryImaging & blood flow

Hospitals counted here

  1. Jiangsu Province Hospital3
  2. Affiliated Brain Hospital of Nanjing Medical University2
  3. Affiliated Suzhou Hospital of Nanjing Medical University Counted in the group total1
  4. Changzhou No.2 People's Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Integrative molecular subtyping and diagnostic model construction for Moyamoya disease based on diverse programmed cell death gene patterns.2025Orphanet journal of rare diseasesFree full text
  2. Single-cell sequencing analysis of peripheral blood in patients with moyamoya disease.2023Orphanet journal of rare diseasesFree full text
  3. Construction of Diagnosis Model of Moyamoya Disease Based on Convolution Neural Network Algorithm.2022Computational and mathematical methods in medicineFree full text
  4. Baseline Hemodynamic Impairment and Revascularization Outcome in Newly Diagnosed Adult Moyamoya Disease Determined by Pseudocontinuous Arterial Spin Labeling.2022World neurosurgery
  5. High-resolution compressed sensing time-of-flight MR angiography outperforms CT angiography for evaluating patients with Moyamoya disease after surgical revascularization.2022BMC medical imagingFree full text
Trials on ClinicalTrials.gov3
  1. Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.Enrolling by invitationNCT07894640Lead sponsorEarly phase 1Start 2024-12
  2. Fufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya DiseaseEnrolling by invitationNCT07875335Lead sponsorN/AStart 2024-12
  3. Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical PneumoniaEnrolling by invitationNCT07906652Lead sponsorEarly phase 1Start 2024-12

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.5%Leads about 1 in 67 of China's research papers on Wilson disease ▼ from 2.1%

Led 3 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren

Hospitals counted here

  1. Women's Hospital, Nanjing Medical University Counted in the group total1
  2. Child Health Care Hospital1
  3. Children's Hospital of Nanjing Medical University Counted in the group total1
  4. Affiliated Taizhou People's Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
4.2%Leads about 1 in 24 of China's research papers on Biliary atresia ▲ from 0.8%

Led 9 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
2
Share of China's trials
10.0%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesDisease mechanismsKasai operationScreening & diagnosis

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Children's Hospital of Nanjing Medical University9
  2. Jiangsu Province Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
2.6%Leads about 1 in 38 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 4.0%

Led 7 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Affiliated Brain Hospital of Nanjing Medical University5
  2. Wuxi Children's Hospital, Nanjing Medical University1
  3. Children's Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.6%Leads about 1 in 62 of China's research papers on Takayasu arteritis ▲ from 0.7%

Led 3 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Jiangsu Province Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatic echinococcosis

肝包虫病
1.3%Leads about 1 in 76 of China's research papers on Hepatic echinococcosis New since 2021

Led 2 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (32.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Third Affiliated Hospital of Nanjing Medical University1
  2. Second Affiliated Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.9%Leads about 1 in 52 of China's research papers on Idiopathic pulmonary fibrosis

Led 19 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
19
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.9%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis ▲ from 0.3%

Led 7 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

Hospitals counted here

  1. Jiangsu Province Hospital4
  2. Affiliated Jiangsu Shengze Hospital of Nanjing Medical University1
  3. Second Affiliated Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
4.1%Leads about 1 in 24 of China's research papers on Fabry disease New since 2021

Led 3 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Taizhou People's Hospital of Nanjing Medical University1
  2. Women's Hospital, Nanjing Medical University1
  3. Jiangsu Province Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.4%Leads about 1 in 71 of China's research papers on Duchenne muscular dystrophy ▼ from 2.0%

Led 3 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. Women's Hospital, Nanjing Medical University1
  2. Child Health Care Hospital1
  3. Gynecology Hospital, Nanjing Medical University1
  4. Jiangsu Province Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.6%Leads about 1 in 61 of China's research papers on Behçet disease ▲ from 0.7%

Led 4 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Children's Hospital of Nanjing Medical University2
  2. Second Affiliated Hospital of Nanjing Medical University1
  3. Affiliated Stomatological Hospital of Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.1%Leads about 1 in 92 of China's research papers on IgA nephropathy

Led 8 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Affiliated Wuxi People's Hospital of Nanjing Medical University1
  2. Wuxi People's Hospital, Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
2.0%Leads about 1 in 50 of China's research papers on Primary sclerosing cholangitis

Led 2 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

Hospitals counted here

  1. Jiangsu Province Hospital1
  2. Wuxi People's Hospital, Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
5.6%Leads about 1 in 18 of China's research papers on Hirschsprung disease ▼ from 17.4%

Led 9 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
2
Share of China's trials
16.7%
Share of the world's papers
1.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

Hospitals counted here

  1. Children's Hospital of Nanjing Medical University8
  2. Childre's Hospital, Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
5.1%Leads about 1 in 20 of China's research papers on Familial adenomatous polyposis ▲ from 2.0%

Led 3 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Jiangsu Province Hospital2
  2. Affiliated Hospital, Nanjing Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov